Axsome Therapeutics (AXSM) announced that SYMBRAVO is now available by prescription in the United States for the acute treatment of migraine with or without aura in adults. SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that targets multiple brain pathways underlying a migraine attack. SYMBRAVO rapidly provides migraine pain freedom and returns patients to normal functioning at 2 hours versus placebo, with lasting pain freedom sustained from 2 to 24 hours in some patients after a single dose.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Positive Outlook for Axsome Therapeutics Despite Regulatory Setback, Driven by Promising Pipeline and Market Potential
- Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05
- Axsome Therapeutics Shareholders Approve Key Proposals at Meeting
- Axsome’s AXS-14 gets regulatory setback with RTF, says Morgan Stanley
- Axsome Therapeutics’ Growth Prospects Remain Strong Despite FDA Setback on AXS-14